233 related articles for article (PubMed ID: 33330386)
1. Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.
Wang Q; Zhao WC; Fu XQ; Zheng QC
Front Chem; 2020; 8():597495. PubMed ID: 33330386
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of SHP2 activation by PD-1 stimulation.
Marasco M; Berteotti A; Weyershaeuser J; Thorausch N; Sikorska J; Krausze J; Brandt HJ; Kirkpatrick J; Rios P; Schamel WW; Köhn M; Carlomagno T
Sci Adv; 2020 Jan; 6(5):eaay4458. PubMed ID: 32064351
[TBL] [Abstract][Full Text] [Related]
3. Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect.
Cheng Y; Ouyang W; Liu L; Tang L; Zhang Z; Yue X; Liang L; Hu J; Luo T
Phys Chem Chem Phys; 2024 Mar; 26(12):9155-9169. PubMed ID: 38165855
[TBL] [Abstract][Full Text] [Related]
4. Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors.
Xu X; Masubuchi T; Cai Q; Zhao Y; Hui E
Elife; 2021 Nov; 10():. PubMed ID: 34734802
[TBL] [Abstract][Full Text] [Related]
5. Probing the Immunoreceptor Tyrosine-Based Inhibition Motif Interaction Protein Partners with Proteomics.
Gao Y; Xing S; Hu L
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731468
[TBL] [Abstract][Full Text] [Related]
6.
Marasco M; Kirkpatrick JP; Carlomagno T
Biomol NMR Assign; 2020 Oct; 14(2):179-188. PubMed ID: 32236803
[TBL] [Abstract][Full Text] [Related]
7. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
Calligari P; Santucci V; Stella L; Bocchinfuso G
Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
[TBL] [Abstract][Full Text] [Related]
8. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
[TBL] [Abstract][Full Text] [Related]
9. Study on the allosteric activation mechanism of SHP2
Liu L; Cheng Y; Zhang Z; Li J; Geng Y; Li Q; Luo D; Liang L; Liu W; Hu J; Ouyang W
Phys Chem Chem Phys; 2023 Sep; 25(35):23588-23601. PubMed ID: 37621251
[TBL] [Abstract][Full Text] [Related]
10. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
Anselmi M; Hub JS
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
[TBL] [Abstract][Full Text] [Related]
11. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
Anselmi M; Hub JS
Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
[TBL] [Abstract][Full Text] [Related]
12. Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network.
Marasco M; Kirkpatrick J; Nanna V; Sikorska J; Carlomagno T
Comput Struct Biotechnol J; 2021; 19():2398-2415. PubMed ID: 34025932
[TBL] [Abstract][Full Text] [Related]
13. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation.
Patsoukis N; Duke-Cohan JS; Chaudhri A; Aksoylar HI; Wang Q; Council A; Berg A; Freeman GJ; Boussiotis VA
Commun Biol; 2020 Mar; 3(1):128. PubMed ID: 32184441
[TBL] [Abstract][Full Text] [Related]
14. Uncoupling ITIM receptor G6b-B from tyrosine phosphatases Shp1 and Shp2 disrupts murine platelet homeostasis.
Geer MJ; van Geffen JP; Gopalasingam P; Vögtle T; Smith CW; Heising S; Kuijpers MJE; Tullemans BME; Jarvis GE; Eble JA; Jeeves M; Overduin M; Heemskerk JWM; Mazharian A; Senis YA
Blood; 2018 Sep; 132(13):1413-1425. PubMed ID: 29891536
[TBL] [Abstract][Full Text] [Related]
15. Revealing Allostery in PTPN11 SH2 Domains from MD Simulations.
Anselmi M; Hub JS
Methods Mol Biol; 2023; 2705():59-75. PubMed ID: 37668969
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory Receptor Trap: A Platform for Discovery of Inhibitory Receptors That Utilize Inositol Lipid and Phosphotyrosine Phosphatase Effectors.
Crute BW; Sheraden R; Ott VL; Harley ITW; Getahun A; Cambier JC
Front Immunol; 2020; 11():592329. PubMed ID: 33193438
[TBL] [Abstract][Full Text] [Related]
17. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
[TBL] [Abstract][Full Text] [Related]
18. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.
Wang Q; Zhao WC; Fu XQ; Zheng QC
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562680
[TBL] [Abstract][Full Text] [Related]
20. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
Song Y; Zhao M; Wu Y; Yu B; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
